Chile expect to have vaccinated at the end of next June to 80% of the population of the country susceptible to be inoculated against the COVID-19, with which it would achieve herd immunity, while maintaining negotiations with the laboratories for the supply of doses in the coming years.
This was expressed on Monday by the country’s Ministers of Health and Science, Enrique Paris and Andrés Couve, respectively, at a press conference with foreign correspondents in which Rodrigo Yáñez, Undersecretary of International Economic Relations of the Foreign Ministry, also participated.
“During the first semester the vaccine that we have has to be available to those over 16 years of age who require it. We have to vaccinate 80% of the population likely to be vaccinated and with that we hope to obtain the herd effect“said Paris.
The minister emphasized that it is the percentage of the population that can be vaccinated and that it is not possible to aspire to 100% both because injecting the vaccine is voluntary, and because so far they are not approved for pregnant women or infants and not for minors. 16 years old.
With more than 3.3 million people vaccinated out of the 19 million inhabitants that the country has, Chile is the country that advances the fastest inoculation in Latin America, ahead of giants such as Argentina, Brazil and Mexico, and is among the top ten in the world according to the “Our World in Data” registry of the University of Oxford.
The country has committed more than 35 million vaccines, of which ten million are Pfizer-BioNTech, another ten million Sinovac and the rest of AstraZeneca, Janssen (Johnson & Johnson) and the platform Covax, promoted by the World Health Organization (WHO) to guarantee universal access to the eventual vaccine.
Supply for the next two years
Of all of them, 8.3 million doses have already reached Chile while the authorities are working to ensure the supply also for the vaccination campaigns in the coming years, so the use of vaccines continues to be evaluated. Johnson & Johnson, the Russian Sputnik V from the laboratory Gamaleya and the Chinese Sinopharm Y CanSino.
“It is important to emphasize that today we are in the first vaccination campaign, that we have many uncertainties regarding how this will continue in the coming years and therefore it is very important to have the options open today and also have them open for the future,” he said Couve.
In this sense, Yáñez referred to the talks to bring doses of the Chinese vaccine to the country CanSino and from the russian Sputnik V and said that at this time “it is still not clear what role these vaccines could play” in the future calendar of Chile nor what amount could come “because they are negotiations in progress.”
The undersecretary explained that at this time the budget law of Chile It establishes an item of 200 million this year for vaccines against the coronavirus but that item will have to increase to a figure close to 300 million dollars.
“We cannot save ourselves”
During his speech, Paris referred to the need to create collaborative networks at the international level to get the vaccine to countries that are not managing to acquire it.
“I believe that in this aspect there must be solidarity, we cannot save ourselves, on the contrary, we have to save ourselves all together”said Paris, who pointed to the importance of Covax mechanism to get the vaccine to countries that have difficulty receiving it.
Covax is a platform coordinated by the WHO to which some 190 countries of the world have adhered in order to have guaranteed initial doses to cover at least 3% of the population in the first phases, finally reaching 20%, enough to protect those most at risk .
(Information from EFE)
Newsletter All about the coronavirus
COVID-19 has put everyone on alert. Subscribe to our newsletter All about the coronavirus, where you will find the most relevant daily data in the country and in the world on the progress of the virus and the fight against its spread.
“Living space”: Studies in South Africa have shown that Novavax’s Covid-19 vaccine is not effective against the variant of the virus discovered in that country. Have all developed vaccines presented the same results?